Acessibilidade / Reportar erro

SIMPLIFYING CELIAC DISEASE PREDISPOSING HLA-DQ ALLELES DETERMINATION BY THE REAL TIME PCR METHOD

Simplificação da detecção dos alelos HLA-DQ predisponentes para doença celíaca pelo método de PCR em tempo real

Abstracts

Background

Celiac disease is an autoimmune enteropathy triggered by the ingestion of gluten in genetically susceptible individuals. Genetic susceptibility is associated with two sets of alleles, DQA1*05 - DQB1*02 and DQA1*03 - DQB1*03:02, which code for class II MHC DQ2 and DQ8 molecules, respectively. Approximately 90%-95% of celiac patients are HLA-DQ2 positive, and half of the remaining patients are HLA-DQ8 positive. In fact, during a celiac disease diagnostic workup, the absence of these specific DQA and DQB alleles has a near perfect negative predictive value.

Objective

Improve the detection of celiac disease predisposing alleles by combining the simplicity and sensitivity of real-time PCR (qPCR) and melting curve analysis with the specificity of sequence-specific primers (SSP).

Methods

Amplifications of sequence-specific primers for DQA1*05 (DQ2), DQB1*02 (DQ2), and DQA1*03 (DQ8) were performed by the real time PCR method to determine the presence of each allele in independent reactions. Primers for Human Growth Hormone were used as an internal control. A parallel PCR-SSP protocol was used as a reference method to validate our results.

Results

Both techniques yielded equal results. From a total of 329 samples the presence of HLA predisposing alleles was determined in 187 (56.8%). One hundred fourteen samples (61%) were positive for a single allele, 68 (36.3%) for two alleles, and only 5 (2.7%) for three alleles.

Conclusion

Results obtained by qPCR technique were highly reliable with no discordant results when compared with those obtained using PCR-SSP.

HEADINGS
Celiac disease; HLA-DQ antigens; Histocompatibility testing; Real-time polymerase chain reaction


Contexto

Doença celíaca é uma enteropatia autoimmune desencadeada pela ingestão de gluten em indivíduos geneticamente suscetíveis. Essa suscetibilidade genética está associada a dois conjuntos de alelos, DQA1*05 - DQB1*02 e DQA1*03 - DQB1*03:02, que codificam moléculas MHC de classe II DQ2 e DQ8, respectivamente. Aproximadamente 90%-95% dos pacientes celíacos são HLA-DQ2 positivos, e metade dos restantes são HLA-DQ8 positivos. No diagnóstico da doença celíaca, a ausência desses alelos DQA e DQB específicos possui um elevado valor preditivo negativo.

Objetivo

Nosso objetivo foi melhorar a detecção de alguns alelos predisponentes para doença celíaca, combinando a simplicidade e sensibilidade da técnica de PCR em tempo real (qPCR) e análise da curva de melting com a especificidade dos primers de sequência específica.

Métodos

Primers de sequência específica para DQA1*05 (DQ2), DQB1*02 (DQ2), e DQA1*03 (DQ8) foram usados para testar a presença de cada alelo em reações independentes. Primers para Hormônio de Crescimento Humano foram usados como controle interno. Em paralelo, foi usado um protocolo de PCR-SSP como um método de referência para validar nossos resultados positivos.

Resultados

Das 329 amostras testadas, 187 (56.8%) foram positivas para os alelos HLA predisponentes, usando as duas técnicas. Essas 187 amostras positivas foram subdivididas em 114 (61.0%) positivas para apenas um alelo, 68 (36.3%) para dois alelos e apenas 5 (2.7%) para os três alelos.

Conclusão

Os resultados obtidos pela técnica de qPCR mostraram-se altamente confiáveis, sem resultados discordantes quando comparados àqueles obtidos pelo método PCR-SSP.

DESCRITORES
Doença celíaca; Antígenos HLA-DQ; Teste de histocompatibilidade; Reação em cadeia da polimerase em tempo real


INTRODUCTION

Celiac disease (CD) is an autoimmune enteropathy triggered by the ingestion of gluten in genetically susceptible individuals(22. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology. 2001;120(3):636-51.). Once thought to be a rare disease, CD diagnoses are increasing with current worldwide prevalence at 1% (33. Green PHR, Cellier C. Celiac disease. N Engl J Med. 2007;357(17):1731-43.). Gluten, the primary component of wheat, rye and barley, is the environmental agent responsible for CD. Gluten is difficult to digest because it is rich in proline amino acid residues that tend to be more resistant to gastric and pancreatic enzymatic action. When these long undigested protein fragments undergo deamidation by tissue transglutaminases they become potent immunogenic epitopes. In celiac patients, these gluten-derived peptides bind to Major Histocompatibility Complex [MHC, or Human Leukocyte Antigen (HLA)] Class II molecules eliciting immune stimulation of CD4 T-cells(11. Farrell RJ, Kelly CP. Celiac sprue. N Engl J Med. 2002;346(3):180-8.).

Approximately 60% of the genetic susceptibility to CD is shared by an unknown number of non-HLA genes with each gene estimated to contribute only a small proportion to the total risk effect(1010. Wolters VM, Wijmenga C. Genetic background of celiac disease and its clinical implications. Am J Gastroenterol. 2008;103(1):190-5.); therefore, detection of a single non-HLA gene has a low positive gain in the diagnosis of CD. However, two sets of alleles, DQA1*05 - DQB1*02 and DQA1*03 - DQB1*03:02, which code for class II MHC DQ2 and DQ8 molecules, respectively, are carried by approximately one-third of the general population and account for 40% of the genetic susceptibility to CD(66. Megiorni F, Pizzuti A. HLA-DQA1 and HLA-DQB1 in Celiac disease predisposition: practical implications of the HLA molecular typing. J Biomed Sci. 2012;19:88., 99. Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby E. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med. 1989;169(1):345-50.). In fact, approximately 90%-95% of celiac patients are HLA-DQ2 positive, while half of the remaining patients are HLA-DQ8 positive(44. Karell K, Louka AS, Moodie SJ,Ascher H, Clot F, Greco L, et al. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Human Immunology. 2003;64(4):469-77., 55. Louka AS, Sollid LM. HLA in celiac disease: Unravelling the complex genetics of a complex disorder. Tissue Antigens. 2003;61(2):105-17.). In addition, during a CD diagnostic workup, the absence of these specific DQA and DQB alleles has a near perfect negative predictive value(1010. Wolters VM, Wijmenga C. Genetic background of celiac disease and its clinical implications. Am J Gastroenterol. 2008;103(1):190-5.).

Being able to quickly and efficiently determine the status of these DQA and DQB alleles in potential CD patients or risk populations (celiac disease patient’s first degree relatives, people with related autoimmune diseases, among others) could dramatically aide in diagnostic workups. However, currently available methods for screening of HLA-associated alleles in CD patients, which include Sequence-Specific Oligonucleotide Probe Hybridization (SSOPH), PCR amplification with Sequence-Specific Primers (PCR-SSP), and Sequence-Base Typing (SBT), are expensive and time-consuming. The aim of this study is to simplify the detection of three of these alleles (DQA1*03; DQA1*05; DQB1*02) by developing a real-time PCR (or quantitative PCR, qPCR) protocol with melting curve analysis using Sequence-Specific Primers (SSP) previously developed for PCR-SSP(77. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens. 1993;41(3):119-34.).

METHODS

The study complied with the principles of the latest Declaration of Helsinki (2008) and was approved by the Research Ethics Committee on Medical Sciences of the University of Brasilia, School of Medicine (protocol nº 132/2008).

DNA was extracted from newborn umbilical cord blood (UCB) collected immediately after birth into an EDTA-coated tube. All mothers had previously agreed to participate in the research. DNA extraction was performed using IllustraTM Blood genomic Prep Mini Spin kit (Healthcare, Buckinghamshire, UK) according to the manufacturer’s instructions. Concentration of DNA samples were adjusted to 15 ng/µL after being quantified at Nanodrop ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA), which measures absorbance at 260 nm and 280 nm. Samples were considered suitable for analyses when the ratio of absorbances (A260/A280) was between 1.8 and 2.

Sequence-specific primers for DQA1*05 [(5’-ACGGTCCCTCTGGCCAGTA, 3’-AGTTGGAGCGTTTAATCAGAC) (DQ2)], DQB1*02 [(5’-GTGCGTCTTGTGAGCAGAAG, 3’-GCAAGGTCGTGCGGAGCT) (DQ2)], and DQA1*03 [(5’-TTCACTCGTCAGCTGACCAT, 3’-CAAATTGCGGGTCAAATCTTCT) (DQ8)] previously described by Olerup et al. (1993)(77. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens. 1993;41(3):119-34.) were used to test for the presence of each allele in independent reactions. Primers for Human Growth Hormone (HGH) were used as an internal control(88. Profaizer T, Eckels D, Delgado JC. Celiac disease and HLA typing using real-time PCR with melting curve analysis. Tissue Antigens. 2011;78(1):31-7.). Amplifications were performed on a StepOne Real-Time PCR System (Applied Biosystems-Life Technologies™, Carlsbad, CA, USA). For DQ alleles, amplifications were performed in 20 µL volume containing

2 µL of genomic DNA, 0.5 µM DQ-forward primer, 0.5 µM DQ-reverse primer, and 1X Thermo Scientific AbsoluteQPCR SYBR Green ROX Mix (Thermo Fisher Scientific Inc., Vilnius, Lithuania). For HGH control samples reactions were performed in 20µL volume containing 2 µL of genomic DNA, 0.5 µM HGH-specific forward primer,

0.5 µM HGH-specific reverse primer, and 1X Thermo Scientific Absolute QPCR SYBR Green ROX Mix (Thermo Fisher Scientific Inc., Vilnius, Lithuania). A positive control or reference sample (DNA sample known to be positive for the searched alleles) was included in all reactions to standardize interpretations. Additionally, a known negative DNA sample (not containing the region of interest) and negative control (no DNA added to reaction) were run in set of reactions to test for contamination. PCR and melting curve conditions are detailed in Table 1. Amplified products were analyzed using a melting curve.

TABLE 1.
qPCR conditions including temperature, time, and number of cycles, for DQA1*05, DQB1*02, DQA1*03 alleles and HGH gen

Since this was the first attempt to use this protocol with these alleles, we used a parallel PCR-SSP protocol as a reference method to validate our positive results. The conditions and reactions were performed using DQ-CD Typing Kit Plus (BioDiagene, Palermo, Italy) according to the manufacturer’s recommendations.

RESULTS

Results obtained by qPCR technique were determined to be highly reliable with no discordant results when compared with those obtained using PCR-SSP; however, the latter technique did provide some additional details in terms of homozygosity and heterozygosity, which will be detailed shortly. Using both techniques, from a total of 329 samples, 187 (56.8%) were determined positive for HLA predisposing alleles. With qPCR, these 187 positive samples could be subdivided into 114 (61.0%) positive for a single allele, 68 (36.3%) for two alleles, and only 5 (2.7%) for three alleles (Table 2). The evidenced mean Tm for the three analyzed alleles were 80.12 ± 0.1ºC for DQA1*05; 86.49 ± 0.13ºC for DQB1*02 and 80.69 ± 0.11ºC for DQA1*03, melting curves for each are shown in Figure 1. For the HGH gene, the evidenced mean Tm was 83.5ºC ± 0.1ºC. The most common combination of positive alleles was DQA1*05 and DQB1*02 (Table 2), which code for class II MHC DQ2 molecules. With PCR-SSP, these 187 could be further subdivided to inform whether a sample was heterozygous (DQB1*02/x; n=70; 37.5%) or homozygous (DQB1*02/02 haplotype; n=22; 11.7%) for the β-chain of the DQ2 which allowed to differentiate between haplotypes in cis and trans (Table 2).

TABLE 2.
Summary of the 187 samples that tested positive, with PCR-SSP and qPCR, for one or more of three analyzed HLA predisposing alleles: DQA1*05 (DQ2), DQB1*02 (DQ2), and DQA1*03 (DQ8). The number of individuals (and % of total) determined to be positive at one or more alleles are reported

FIGURE 1.
Melting curves of the analyzed alleles. A: DQA1*05; B: DQB1*02; C: DQA1*03

DISCUSSION

In light of the great need of cost-effective and specific assays for the determination of celiac associated HLA alleles (especially in high-risk populations), we successfully developed a qPCR technique that uses PCR-SSP primers. As we chose to use primers that were originally designed to be used with PCR-SSP method(77. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens. 1993;41(3):119-34.), all qPCR results were confirmed using a reference method (DQ-CD TypingKitPlus). The qPCR-based typing system, despite its incapability to determine DQB1*02 allele homozygosis, proved to be highly reliable with no discordant results compared with the ones obtained with PCR-SSP. Determination of DQB1*02 homozygosis, although important when estimation of risk of having celiac disease is pursued, has a low relevance when the goal is to identify, inside a high risk population, which patients must be followed up, as was intended in this work.

Considering that qPCR procedures are faster, comprise fewer handling steps and are highly sensitive; we can affirm that this study managed to combine the simplicity of real-time PCR with the specificity of PCR-SSP. This makes it an excellent candidate when it comes to clinics, both in the detection of the genetic bases of the disease in a patient, for later familiar screenings to detect predisposition of developing the disease, and in the main role of HLA typing that lies in its high negative predictive value to exclude CD (close to 100%) (1010. Wolters VM, Wijmenga C. Genetic background of celiac disease and its clinical implications. Am J Gastroenterol. 2008;103(1):190-5.). Moreover, the fact of being a simple laboratory technique with few requirements, both in handling steps and equipments, can sometimes make the difference between finishing or not a scientific work for some scientist of developing countries who, like us, do not always have access to imported commercial kits or even having, the delay in arriving could interfere in the development of our work. One of the limitations of this study was not having analyzed the DQB1*03:02 allele, which is also associated with celiac disease. The reason for that was that the par of primers cited by Olerup et al. (1993), for this allele, also amplified DQB1*03:03 which is not related to celiac disease, giving false positive results. However, in our laboratory routine, we obtained excellent results by using the DQB1*03:02 primers used by Profaizer et al. (2001), and reproducing the qPCR conditions cited by the author.

ACKNOWLEDGMENTS

We thank the “Coordenação de Aperfeiçoamento de Pessoal de nível Superior” (CAPES) and the “Fundação de Apoio a Pesquisa do Distrito Federal” (FAPDF) for their financial support.

Authors’ contributions

Selleski N participated in the study analysis and drafted the manuscript. Almeida LM e Almeida FC were involved in study design and data analysis. Gandolfi L participated in recruitment, data collection and data analysis. Pratesi R conceived the study and contributed to data collection and statistical analysis. Nóbrega YKM helped with data analysis and supervised the study design and coordination. All authors read and approved the final manuscript.

REFERENCES

  • 1
    Farrell RJ, Kelly CP. Celiac sprue. N Engl J Med. 2002;346(3):180-8.
  • 2
    Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology. 2001;120(3):636-51.
  • 3
    Green PHR, Cellier C. Celiac disease. N Engl J Med. 2007;357(17):1731-43.
  • 4
    Karell K, Louka AS, Moodie SJ,Ascher H, Clot F, Greco L, et al. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Human Immunology. 2003;64(4):469-77.
  • 5
    Louka AS, Sollid LM. HLA in celiac disease: Unravelling the complex genetics of a complex disorder. Tissue Antigens. 2003;61(2):105-17.
  • 6
    Megiorni F, Pizzuti A. HLA-DQA1 and HLA-DQB1 in Celiac disease predisposition: practical implications of the HLA molecular typing. J Biomed Sci. 2012;19:88.
  • 7
    Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens. 1993;41(3):119-34.
  • 8
    Profaizer T, Eckels D, Delgado JC. Celiac disease and HLA typing using real-time PCR with melting curve analysis. Tissue Antigens. 2011;78(1):31-7.
  • 9
    Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby E. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med. 1989;169(1):345-50.
  • 10
    Wolters VM, Wijmenga C. Genetic background of celiac disease and its clinical implications. Am J Gastroenterol. 2008;103(1):190-5.
  • Disclosure of funding: no funding received

Publication Dates

  • Publication in this collection
    Apr-Jun 2015

History

  • Received
    22 July 2014
  • Accepted
    23 Oct 2014
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE. Rua Dr. Seng, 320, 01331-020 São Paulo - SP Brasil, Tel./Fax: +55 11 3147-6227 - São Paulo - SP - Brazil
E-mail: secretariaarqgastr@hospitaligesp.com.br